Immunoinformatics Approach to Design a Chimeric CD70-Peptide Vaccine against Renal Cell Carcinoma

Area of Science:

• Immunology and Bioinformatics
• Oncology and Vaccine Development

Background:

• Renal cell carcinoma (RCC) is a leading cause of cancer-related mortality globally.
• Overexpression of CD70 is associated with advanced RCC stages, making it a potential therapeutic target.

Purpose of the Study:

• To design and computationally evaluate a multiepitope vaccine targeting CD70 for RCC treatment.
• To enhance vaccine immunogenicity and stability using cell-penetrating peptides and tumor necrosis factor-alpha.

Main Methods:

• In silico construction of chimeric multiepitope vaccines by linking CD70 epitopes with CPP and TNF-α.
• Computational assessment of antigenicity, allergenicity, toxicity, population coverage, and physicochemical properties.
• Structural analysis including B-cell epitope prediction, molecular docking, molecular dynamics simulation, and immune response simulation.

Main Results:

• Constructed vaccines were antigenic, non-toxic, non-allergenic, and showed favorable physicochemical properties with broad population coverage.
• Molecular docking and dynamics simulations indicated stable interactions between the vaccine construct (CD70-CPP-TNF) and the TNF receptor.
• In silico cloning was achieved, and the vaccine demonstrated potential to modulate humoral and cellular immune responses.

Conclusions:

• The chimeric CD70-CPP-TNF vaccine exhibits promising therapeutic potential against RCC based on computational analyses.
• Further in vitro and in vivo experimental validation is required to confirm the efficacy and safety of this novel vaccine candidate.